WP Advisors LLC reduced its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 7.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,839 shares of the medical research company’s stock after selling 377 shares during the quarter. Amgen accounts for approximately 0.8% of WP Advisors LLC’s holdings, making the stock its 22nd biggest position. WP Advisors LLC’s holdings in Amgen were worth $842,000 as of its most recent SEC filing.
A number of other large investors also recently added to or reduced their stakes in AMGN. Toronto Dominion Bank increased its holdings in Amgen by 11.0% in the 3rd quarter. Toronto Dominion Bank now owns 279,280 shares of the medical research company’s stock valued at $52,066,000 after buying an additional 27,726 shares during the period. Teacher Retirement System of Texas increased its holdings in Amgen by 16.5% in the 3rd quarter. Teacher Retirement System of Texas now owns 740,764 shares of the medical research company’s stock valued at $138,115,000 after buying an additional 104,871 shares during the period. Putnam FL Investment Management Co. bought a new stake in shares of Amgen in the 3rd quarter worth about $447,000. Moody Lynn & Lieberson LLC bought a new stake in shares of Amgen in the 3rd quarter worth about $2,353,000. Finally, Patten Group Inc. grew its holdings in shares of Amgen by 1,151.5% in the 3rd quarter. Patten Group Inc. now owns 27,859 shares of the medical research company’s stock worth $389,000 after purchasing an additional 25,633 shares during the last quarter. Hedge funds and other institutional investors own 79.50% of the company’s stock.
In related news, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction that occurred on Wednesday, February 14th. The stock was sold at an average price of $174.18, for a total transaction of $265,624.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.19% of the stock is currently owned by corporate insiders.
Shares of Amgen stock traded down $1.51 during trading hours on Monday, hitting $186.73. 239,173 shares of the company were exchanged, compared to its average volume of 5,383,164. The firm has a market cap of $135,638.63, a P/E ratio of 73.25, a price-to-earnings-growth ratio of 2.31 and a beta of 1.37. The company has a quick ratio of 5.17, a current ratio of 5.49 and a debt-to-equity ratio of 1.35. Amgen, Inc. has a 1-year low of $152.16 and a 1-year high of $201.23.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, February 1st. The medical research company reported $2.89 earnings per share for the quarter, missing analysts’ consensus estimates of $3.03 by ($0.14). The firm had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.84 billion. Amgen had a net margin of 8.66% and a return on equity of 30.87%. The business’s revenue was down 2.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.89 earnings per share. equities analysts anticipate that Amgen, Inc. will post 13.25 earnings per share for the current year.
Amgen announced that its board has initiated a share repurchase program on Thursday, February 1st that allows the company to buyback $10.00 billion in shares. This buyback authorization allows the medical research company to repurchase shares of its stock through open market purchases. Shares buyback programs are often an indication that the company’s board believes its shares are undervalued.
The firm also recently announced a quarterly dividend, which will be paid on Friday, June 8th. Investors of record on Thursday, May 17th will be paid a dividend of $1.32 per share. The ex-dividend date is Wednesday, May 16th. This represents a $5.28 dividend on an annualized basis and a yield of 2.83%. Amgen’s payout ratio is 205.45%.
Several equities research analysts have recently weighed in on the stock. Vetr raised shares of Amgen from a “sell” rating to a “hold” rating and set a $181.60 target price on the stock in a report on Tuesday, February 27th. Oppenheimer set a $205.00 target price on shares of Amgen and gave the stock a “buy” rating in a report on Friday, January 5th. Atlantic Securities lowered shares of Amgen from an “overweight” rating to a “neutral” rating and set a $187.01 target price on the stock. in a report on Monday, February 5th. Piper Jaffray Companies lowered their target price on shares of Amgen from $194.00 to $190.00 and set an “overweight” rating on the stock in a report on Friday, February 2nd. Finally, Cann reaffirmed a “buy” rating and issued a $205.00 target price on shares of Amgen in a report on Thursday, November 30th. One analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $191.72.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://ledgergazette.com/2018/03/19/amgen-inc-amgn-shares-sold-by-wp-advisors-llc.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.